Frank S. David, MD, PhD leads the biopharma consulting firm Pharmagellan, where he advises drug companies and investors on R&D and business strategy. He is also an academic researcher on strategy, regulation, and policy in the drug industry; a member of the Harvard-MIT Center for Regulatory Science; and a former blogger at Forbes.com.
A key issue about drug pricing not covered in Kolchinsky's book relates to value: even if a new therapy is affordable, is it "worth it"? Health economist Peter Neumann and his colleagues have written an authoritative, insightful, and extremely accessible history of efforts to align drugs' prices with their benefits to patients and society. This is a must-read guide for both insiders and non-experts to a topic that will be at the forefront of the drug pricing debate in the coming decade.
The US prescription drug business is a $500 billion industry whose rising prices carry profound consequences for patients, caregivers, employers and taxpayers across the nation. In the United States, average prices of leading brand-name drugs are two to four times higher than prices charged in other wealthy countries, raising questions as to what Americans are getting for the extra expense. On the other hand, healthy industry returns have arguably fueled life-saving innovation. With the advent of ever more targeted and powerful treatments, including cell- and gene-based therapies with multi-million-dollar price tags, the need for sensible drug pricing policies will only…
This was part
of my research for a historical novel I am writing, and this book is a fascinating read.
From
items that sound rather nice (cold cream made with almond oil, jojoba oil, beeswax, and rose water) to the really quite disgusting (brushing your teeth
with a mix of castile soap and vodka, anyone?), this has recipes, anecdotes,
historical customs and brand names galore. Wonderful for research.
Ties in to a fantastic new four-part BBC series from the makers of the hit Victorian Farm
Shows how many products on sale in our high street chemists today can trace their origins back to nineteenth century formulations
Full of fascinating facts, remedies and recipes to try at home
Victorian Farm sold over 40,000 copies (Nielsen Bookscan figures)
This is the story of consumer medicine - how high street healthcare emerged in just 50 years and how we still rely on hundreds of formulations and products that can trace their origins back to the nineteenth century.
In my younger days, as the son of a medical professor and a public health nurse, I was more interested in healing society than patients. But my political interests and research agenda as a professor of political science ultimately led back to medicine. I found that profit-maximizing market competition in health care failed miserably to promote value in therapeutics and economize on society’s scarce resources. I became aware of the neglect of public health to prevent disease for vulnerable groups in society and save money as well as lives. Pervasive and enduring economic conflicts of interest in the medical-industrial complex bear primary responsibility for severe deficits in quality, equality, and economy in American health care.
If you think that medical journals published by respected medical societies are full of good science, think again.
For me, Abramson’s Sickeningnailed the case for a conclusion that the net effect of the many hundreds of medical journals published here and around the world is to subtract from the sum of human medical knowledge.
Abramson, as an expert witness in criminal and civil cases against drug companies, draws in part on subpoenaed documents to expose how medical science, as part of the entire medical-industrial complex, is corrupted from start to finish by the drug industry’s funding of most clinical trials, their control over the data analysis, and even their ghost-writing of articles submitted to journals.
New and disturbing was the withholding of clinical trials’ raw data from journals’ peer reviewers. Instead, they get biased summaries bearing drug manufacturers’ fingerprints.
The inside story of how Big Pharma’s relentless pursuit of ever-higher profits corrupts medical knowledge—misleading doctors, misdirecting American health care, and harming our health.
The United States spends an excess $1.5 trillion annually on health care compared to other wealthy countries—yet the amount of time that Americans live in good health ranks a lowly 68th in the world. At the heart of the problem is Big Pharma, which funds most clinical trials and therefore controls the research agenda, withholds the real data from those trials as corporate secrets, and shapes most of the information relied upon by health care professionals.…
I am an economist who came to realize that the marketplace of ideas was a political doctrine, and not an empirical description of how we came to know what we think we know. Science has never functioned in the same manner across centuries; it was only during my lifetime that it became recast as a subset of market reality. I have spent a fair amount of effort exploring how economics sought to attain the status of a science; but now the tables have turned. It is now scientists who are trained to become first and foremost market actors, finally elevating the political dominance of the economists.
A best-seller in the UK, it never garnered the attention it deserved in the US. As a trained physician, Goldacre explains why doctors cannot trust the information concerning prescription drugs that is made available to them, and why this should concern every patient. The incentives motivating drug regulators constitute a big part of the problem, but the actual conduct of clinical trials comes in for intensive scrutiny as well. The rigors of double-blinded trials are useless if owners of the data can hide whatever outcomes they don’t like. His chapter on how to bend a clinical trial has become a classic.
"Smart, funny, clear, unflinching: Ben Goldacre is my hero." ―Mary Roach, author of Stiff, Spook, and Bonk
We like to imagine that medicine is based on evidence and the results of fair testing and clinical trials. In reality, those tests and trials are often profoundly flawed. We like to imagine that doctors who write prescriptions for everything from antidepressants to cancer drugs to heart medication are familiar with the research literature about these drugs, when in reality much of the research is hidden from them by drug companies. We like to imagine that doctors are impartially educated, when in reality…
Wonder Drug covers the startling untold story of Thalidomide, a sleeping pill, in the USA.
The standard story is that the tenacity of two women Frances Kelsey and Helen Taussig supposedly kept this drug that caused horrific birth defects off the market. The facts are that drug company machinations and FDA incompetence meant thousands of pregnant women had this drug and hundreds of babies were deformed and disappeared.
Kelsey and Taussig had a token triumph, but the company escaped blame, FDA bureaucracy increased dramatically in size, and the bureaucrats seem as tightly enmeshed with companies now as they were in 1960-1962.
It is difficult to know whether we learnt anything from Thalidomide, other than the amazing spirit the children affected have since displayed.
Longlisted for the Andrew 2024 Carnegie Medal for Non-Fiction
The shocking, never-before-told story of America's thalidomide victims
In Germany on Christmas Day 1956 a baby girl was born without ears. She was the first victim of the notorious thalidomide epidemic. There would be over 10,000 more across 46 countries.
For years the world believed the United States had avoided the catastrophe. After Frances Kelsey at the Food and Drug Administration became suspicious of the dangers of thalidomide in 1960, she led a successful fight to block its commercial approval.
But now, having probed government and corporate archives and interviewed hundreds…
I have been a writer for thirty years and a horse lover my entire life. When I decided to write There Must Be Horses, I set out to learn about natural horsemanship and the way horses and people relate to each other. Of course, I then needed to try out all those exciting ideas myself so I bought myself a horse to help with my research. That was my excuse anyway – in truth I was finally fulfilling my childhood dream of a pony of my own. I still have that horse and would never part with him. He’s an important part of our family.
One of the main characters of this novel is a horse whisperer whose traumatic experiences on his eighth birthday have left him unable to speak. When he hears about stallions who are kept entirely indoors in order to produce a new drug, he sets out to ease their suffering. In the process, he meets Karen Lawford, the workaholic heir to the drug company, and tries to reawaken her love for horses so she can see that what is happening to the stallions is wrong, and tries to help her too. I love this well-crafted story of love and healing, but feel I should mention that it includes horses dying and being badly treated.
Outback horseman Lane Dimity is one of the most powerful social media personalities on the planet. Although unable to speak since the tragedy that took place on his eighth birthday, his words reach out across the world, changing lives. When he learns that more than a thousand stallions have been bred by the U.S. pharmaceutical company Pilatos, he is determined to free them. The heir to Pilatos, Karen Lawford, will do everything in her power to stop him.
Pilatos has gambled its future on the revolutionary drug Stablex, and the genetically unique stallions are needed to produce it...and there are…
As a published author, Debra’s passion for fast-paced, unputdownable novels is unquenchable. She can be ruthless in her criticism, applying the rule, “three strikes and you’re out!” A firm believer that life is too short to read mediocre books, if she isn’t grabbed by chapter 3, she puts the book down and moves on. She wants a book to make her life better, she wants to feel excitement at picking it back up again, and burying herself in the characters and moods, twists and turns, of a great story. Her writing reflects this same trait, if her words won’t keep the reader totally engrossed, then she won’t write them.
One of my all-time favourites I’ve read this book 3 times now and, after this review, I’m sure I’ll be tempted to indulge myself for a fourth time. Follett is the master of knife-edge thrillers, if you’ve never read him, start now. Full of treachery and violence, twists and revelations. It’s a scary, but utterly brilliant read.
"Everyone likes a page-turner, and Follett is the best." -The Philadelphia Inquirer
"A hell of a storyteller" (Entertainment Weekly), #1 New York Times bestselling author Ken Follett reinvents the thriller with each new novel. But nothing matches the intricate knife-edge drama of Whiteout. . . .
A missing canister of a deadly virus. A lab technician bleeding from the eyes. Toni Gallo, the security director of a Scottish medical research firm, knows she has problems, but she has no idea of the nightmare to come.
As a Christmas Eve blizzard whips out of the north, several people, Toni among them,…
Frank S. David, MD, PhD leads the biopharma consulting firm Pharmagellan, where he advises drug companies and investors on R&D and business strategy. He is also an academic researcher on strategy, regulation, and policy in the drug industry; a member of the Harvard-MIT Center for Regulatory Science; and a former blogger at Forbes.com.
This account of the early years of Vertex Pharmaceuticals, from its inception as a scrappy start-up to its early work in HIV, is a must-read classic for anyone interested in how science turns into new drugs. Barry Werth’s journalistic play-by-play is a cinematic, true-to-life picture of the strategic decisions, real-world challenges, and larger-than-life personalities that underlie modern drug development. His riveting follow-up, The Antidote, continues the saga by taking readers through Vertex’s pathbreaking work to transform the care of patients with hepatitis C and cystic fibrosis.
I am peculiar. Really. I’m an autistic, non-binary, PhD historian who writes weird non-fiction books—and I read them, too. Among my friends are folks like Mary Roach (Fuzz, Stiff, Bonk, Gulp), Deborah Blum (Poisoner’s Handbook), and Ed Yong (I contain Multitudes, An Immense World). Yet, despite there being so many amazing books about strange facts, it's still hard to find them in one place. Your average bookstore doesn’t have a “peculiar” section, for some reason. That’s why I started myPeculiar Book ClubYouTube show: I wanted there to be a home for authors and readers of the quirky, quizzical, curious, and bizarre. And then I thought, hey, why not make a book list, too.
Two pharmacists sit in a Boston courtroom accused of murder. The weapon: a fungus. The death count: 100 and rising. These facts set the stage for a true-crime thriller by investigative journalist Jason Dearen, and it has the makings of a horror movie. There’s scientific hubris, sketchy ethics, a cover-up, and a monster, too: a slimy, sticky, fungal mold that infected patients and began eating their brains alive. It’s riveting, packed with information about how fungal spores managed to contaminate a medical supply chain, and frankly hard to put down. I have done my share of forensic research, and never have I encountered killer fungus before; I consider this an unmissable book.
An award-winning investigative journalist's horrifying true crime story of America's deadliest drug contamination outbreak and the greed and deception that fueled it.
Two pharmacists sit in a Boston courtroom accused of murder. The weapon: the fungus Exserohilum rostratum. The death count: 100 and rising. Kill Shot is the story of their hubris and fraud, discovered by a team of medical detectives who raced against the clock to hunt the killers and the fungal meningitis they'd unleashed.
"Bloodthirsty" is how doctors described the fungal microbe that contaminated thousands of drug vials produced by the New England Compounding Center (NECC). Though NECC…
In my younger days, as the son of a medical professor and a public health nurse, I was more interested in healing society than patients. But my political interests and research agenda as a professor of political science ultimately led back to medicine. I found that profit-maximizing market competition in health care failed miserably to promote value in therapeutics and economize on society’s scarce resources. I became aware of the neglect of public health to prevent disease for vulnerable groups in society and save money as well as lives. Pervasive and enduring economic conflicts of interest in the medical-industrial complex bear primary responsibility for severe deficits in quality, equality, and economy in American health care.
I find Angell’sThe Truth About the Drug Companies extremely valuable for teaching students about how the pharmaceutical industry translates high profits into power resources to protect and increase those profits over time.
The former New England Journal of Medicine editor exposed how drug companies enlist politicians, the FDA, and medical academia for their cause. And armies of lawyers to extend monopoly marketing rights for years.
It was my first introduction to how they spend more on marketing than research, much of that on “copy-cat” drugs of dubious superiority to ones with expired patents.
As a tax (and high drug price) payer, I was disturbed to learn how they use government funds for basic research and then rig and spin their reporting of clinical studies to inflate their products’ therapeutic value and underplay their risks.
During her two decades at The New England Journal of Medicine, Dr. Marcia Angell had a front-row seat on the appalling spectacle of the pharmaceutical industry. She watched drug companies stray from their original mission of discovering and manufacturing useful drugs and instead become vast marketing machines with unprecedented control over their own fortunes. She saw them gain nearly limitless influence over medical research, education, and how doctors do their jobs. She sympathized as the American public, particularly the elderly, struggled and increasingly failed to meet spiraling prescription drug prices. Now, in this bold, hard-hitting new book, Dr. Angell exposes…
